DGAM
TEVA icon

Desjardins Global Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Desjardins Global Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$84.8K Buy
8,123
+1,070
+15% +$9.99K 0.01% 487
2023
Q3 		$71.9K Buy
7,053
+234
+3% +$2.18K 0.01% 504
2023
Q2 		$51.3K Hold
6,819
– – 0.01% 536
2023
Q1 		$60K Buy
+6,819
New +$67.4K 0.01% 510

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Desjardins Global Asset Management's TEVA Position: Q4 2023 in Review

Desjardins Global Asset Management increased its Teva Pharmaceuticals (TEVA) stake by 15% in Q4 2023, buying an estimated $9.99K and bringing the position to 8,123 shares worth $84.8K. The position accounts for 0.01% of the portfolio, ranked #487.

Desjardins Global Asset Management first reported a position in TEVA in Q1 2023 and has held it in 4 quarters since. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Desjardins Global Asset Management held 8,123 shares of Teva Pharmaceuticals worth $84.8K as of Q4 2023.
  • Desjardins Global Asset Management bought 1,070 Teva Pharmaceuticals shares in Q4 2023, an estimated $9.99K.
  • Teva Pharmaceuticals made up 0.01% of Desjardins Global Asset Management's portfolio in Q4 2023, its #487 holding.
  • Desjardins Global Asset Management first reported a position in Teva Pharmaceuticals in Q1 2023 and has held it in 4 quarters since.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Desjardins Global Asset Management's 13F filing for Q4 2023, filed 30 Jan 2024.